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ABSTRACT
Background There is a need for improved selection 
of patients for adjuvant chemotherapy after resection 
of non- metastatic colorectal cancer (CRC). Regulator 
of chromosome condensation 2 (RCC2) is a potential 
prognostic biomarker. We report on the establishment 
of a robust protocol for RCC2 expression analysis and 
prognostic tumour biomarker evaluation in patients who 
did and did not receive adjuvant chemotherapy.
Materials and methods RCC2 was analysed in 2916 
primary CRCs from the QUASAR2 randomised trial and two 
single- hospital Norwegian series. A new protocol using 
fluorescent antibody staining and digital image analysis 
was optimised. Biomarker value for 5- year relapse- free 
survival was analysed in relation to tumour stage, adjuvant 
chemotherapy and the molecular markers microsatellite 
instability, KRAS/BRAFV600E/TP53 mutations and CDX2 
expression.
Results Low RCC2 expression was scored in 41% of 
2696 evaluable samples. Among patients with stage I–III 
CRC who had not received adjuvant chemotherapy, low 
RCC2 expression was an independent marker of inferior 
5- year relapse- free survival in multivariable Cox models 
including clinicopathological factors and molecular 
markers (HR 1.45, 95% CI 1.09 to 1.94, p=0.012, N=521). 
RCC2 was not prognostic in patients who had received 
adjuvant chemotherapy, neither in QUASAR2 nor the 
pooled Norwegian series. The interaction between RCC2 
and adjuvant chemotherapy for prediction of patient 
outcome was significant in stage III, and strongest 
among patients with microsatellite stable tumours 
(p
interaction=0.028).
Conclusions Low expression of RCC2 is a biomarker 
for poor prognosis in patients with stage I–III CRC and 
seems to be a predictive biomarker for effect of adjuvant 
chemotherapy.
INTRODUCTION
Colorectal cancer (CRC) is a global health 
challenge with more than 850 000 regis-
tered deaths each year.1 The management 
of patients with non- metastatic CRC after 
surgery of the primary tumour is primarily 
determined by cancer stage (tumour node 
metastasis (TNM) system), location and toler-
ability to chemotherapy.2 However, more than 
half of the patients with stage II and III colon 
cancer receiving adjuvant chemotherapy are 
cured by surgery alone, while some relapse 
after adjuvant chemotherapy, illustrating that 
current patient selection criteria for adjuvant 
chemotherapy results in substantial over-
treatment and undertreatment.3 Molecular 
Key questions
What is already known about this subject?
 ► Low expression of regulator of chromosome con-
densation 2 (RCC2) has been reported to be associ-
ated with a poor prognosis in colorectal cancer.
 ► High expression of RCC2 has been linked to resis-
tance against chemotherapeutics in cancer cell 
lines.
What does this study add?
 ► The association between low expression of RCC2 
and poor patient prognosis is validated in an inde-
pendent series of colorectal cancer patients, but 
only in those patients who were not treated with 
adjuvant chemotherapy.
 ► A statistically significant interaction was found be-
tween RCC2 expression and chemotherapy with re-
spect to relapse- free survival in stage III colorectal 
cancer.
How might this impact on clinical practice?
 ► If independently validated, expression of RCC2 could 
be included in risk assessments of non- metastatic 
colorectal cancer patients; high expression indicat-
ing a good prognosis and low expression indicating 
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profiling has no impact on adjuvant treatment proto-
cols in stage III, while the microsatellite instability (MSI) 
hypermutator phenotype identifies a low- risk subgroup of 
patients with no predicted benefit from fluoropyrimidine 
chemotherapy in stage II.4
Several molecular tumour markers in addition to MSI 
status have been proposed to improve the risk stratifica-
tion of primary CRCs. Among the most thoroughly inves-
tigated markers are BRAFV600E and KRAS mutations,5 and 
combined analysis of MSI, KRAS and BRAFV600E improves 
the prognostic assessment of stage II/III colon cancers, 
although only modestly when detailed clinicopatho-
logical data are included.6 Markers of infiltrating non- 
malignant cells in the tumour microenvironment may 
have a stronger prognostic potential than the cancer- 
specific genetic markers.7 A prominent stromal compo-
nent indicates a poor patient survival, while infiltrating 
lymphocytes are associated with a favourable outcome.8 9 
The Immunoscore, which is an immunohistochemistry 
(IHC) -based assay for profiling of tumour- infiltrating 
CD3+/total T- cells and CD8+/cytotoxic T- cells, improves 
the prognostic predictive power over clinicopathological 
factors alone.9 This has prompted development of a TNM- 
immune- based risk classification for adjuvant treatment 
decisions, and a recent study of stage III colon cancer 
patients reported a benefit of 6 months vs 3 months treat-
ment with mFOLFOX6 (fluorouracil, leucovorin and 
oxaliplatin) in Immunoscore intermediate/high patients, 
which was not found in Immunoscore low patients.10 Of 
cancer cell- intrinsic markers, the strongest associations 
with benefit from adjuvant chemotherapy in stage III 
CRC have been presented for loss of CDX2 expression, 
although additional supporting data are needed to justify 
clinical use.11 12
Regulator of chromosome condensation 2 (RCC2) 
was originally identified as a 60 kDa protein in a struc-
ture termed the ‘Telophase Disc’ (RCC2 is also known 
as TD-60).13 Functionally, RCC2 is important for proper 
functioning of the chromosomal passenger complex, 
which regulates key aspects of mitosis.14 Additionally, 
RCC2 has been shown to be involved in regulation of 
directional cell migration through its interaction with 
RAC1.15 In recent years, several studies have linked RCC2 
to cancer progression,16–18 and we have reported that loss 
of RCC2 expression was associated with a poor prognosis 
in patients with primary CRC.19 Recently, RCC2 has been 
shown to be under transcriptional regulation by wild- type 
TP53 and loss of RCC2 in colon cancer cells was found to 
promote metastasis in an in vivo mouse model.20 RCC2 
has also been associated with chemotherapy resistance in 
preclinical cancer models.17 21
In this study, we established a robust and accurate 
protocol for in situ analysis of RCC2 protein expression 
based on fluorescent IHC using a validated monoclonal 
antibody. We also investigated the value of RCC2 as a 
biomarker for prediction of patient outcome in relation 
to adjuvant chemotherapy in early stage CRC.
MATERIALS AND METHODS
This study is reported according to the Reporting 
recommendations for tumor marker prognostic studies 
(REMARK) (online supplemental table 1).22
Clinical samples and molecular data
Two independent Norwegian series of primary CRCs (total 
N=1720) and a British clinical trial series (QUASAR2, 
N=1196) were analysed (table 1 and online supplemental 
table 2).
Norwegian series 1 (N=922) and 2 (N=798) were two 
single- hospital series of patients with stage I–IV primary 
CRCs treated by major surgical resection at Oslo University 
Hospital in the time periods 1993–2003 and 2003–2012, 
respectively. The series are population representative for 
the Southeast of Norway and adjuvant chemotherapy was 
administered according to national guidelines. Adjuvant 
chemotherapy has since 1997 been part of standard guide-
lines for stage III and now also for high- risk stage II colon 
cancer patients younger than 76 years. This explains why 
only 58 out of 223 R0- resected stage III patients in the 
first series (1993–2003) received chemotherapy (table 1 
and further details in online supplemental table 2). For 
patients in the second Norwegian series (2003–2012), 
adjuvant chemotherapy was given as standard for stage 
III colon cancer, but on a case- by- case basis according to 
tolerability in patients above 75 years (6 out of 56 R0- re-
sected stage III colon cancer patients above 75 received). 
Adjuvant chemotherapy was also administered according 
to risk assessments in patients with rectal cancer (7 out of 
113 R0- resected stage III rectal cancer patients received 
across the two cohorts). Five- year follow- up for cancer 
recurrence and survival was complete for all patients 
except two (one censored at 4.2 years and one with 
missing information). QUASAR2 was an international, 
multicentre, phase 3, randomised clinical trial, enrolling 
1952 stage III and high- risk stage II CRC patients in the 
time period 2005–2010.23 These patients were randomly 
assigned to receive capecitabine alone or capecitabine 
together with bevacizumab in the adjuvant setting.
Construction of tissue microarrays (TMAs) and molec-
ular analyses in the QUASAR2 cohort were performed as 
previously reported.23–25 Patients from QUASAR2 were 
included in this study based on availability of TMAs and 
clinical data.
For the Norwegian series 1, MSI- status and KRAS- and 
BRAFV600E- mutational status have been published.26 TMAs 
with 0.6 mm diameter cores were built from formalin- 
fixed paraffin- embedded (FFPE) tumour tissue,19 and 
CDX2 expression has been published elsewhere.12 For 
the Norwegian series 2, MSI status, KRAS, BRAFV600E and 
TP53 mutational status, as well as CDX2- expression were 
also previously reported and available for major subsets 
of the samples (see table 1).12 26 27 TMAs were constructed 
with 1.0 mm diameter cores from FFPE blocks, similarly to 
the Norwegian series 1. Deficient mismatch repair status 
was additionally determined by IHC for the mismatch 
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Table 1 Clinicopathological characteristics of the three CRC cohorts







Total patients, N 922 798 1196
Age
  Median (range) 73 (29–94) 72 (27–97) 0.60 65 (21–85)
Sex
  Female 485 (53%) 407 (51%) 0.53 507 (42%)
  Male 437 (47%) 391 (49%) 689 (58%)
TNM stage
  I 137 (15%) 167 (21%) 0.007 –
  II 381 (41%) 288 (36%) 420 (35%)
  III 242 (26%) 214 (27%) 776 (65%)
  IV 159 (17%) 129 (16%) –
  NA 3 – –
Resection status
  R0 719 (78%) 651 (82%) 0.09 1196 (100%)
  R1 36 (4%) 19 (2%) –
  R2 167 (18%) 128 (16%) –
Tumour location
  Right colon 365 (40%) 327 (41%) 0.29 445 (42%)
  Left colon 301 (33%) 239 (30%) 490 (46%)
  Rectum 231 (25%) 218 (27%) 132 (12%)
  Synchronous 25 (3%) 14 (2%) –
  NA – – 129
MSI status
  MSI 128 (15%) 120 (16%) 0.78 154 (13%)
  MSS 712 (85%) 638 (84%) 988 (87%)
  NA 82 40 54
BRAFV6ooE mutational status
  Wild- type 650 (85%) 288 (83%) 0.66 956 (87%)
  Mutated 119 (15%) 57 (17%) 142 (13%)
  NA 153 453 98
KRAS mutational status
  Wild- type 463 (69%) 238 (69%) 0.94 –
  Mutated 204 (31%) 106 (31%) –
  NA 255 454 –
CDX2 expression status
  Positive 568 (89%) 281 (89%) 0.91 –
  Negative 71 (11%) 34 (11%) –
  NA 283 483 –
TP53 mutational status
  Wild- type – 145 (42%) – –
  Mutated – 202 (58%) –
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homolog 2), MSH6 (MutS homolog 6) and PMS2 (PMS1 
homolog 2) in the Norwegian series 2 (online supple-
mental methods).
Individual patient data cannot be shared.
Procedures
Two procedures for IHC- based analyses of cytoplasmic 
RCC2 expression were used. Norwegian series 1 has previ-
ously been analysed for nuclear and cytoplasmic expres-
sion using a standard DAB (3,3'-Diaminobenzidine)- 
based chromogenic protocol and a polyclonal antibody, 
combined with manual scoring of RCC2 staining by 
the Allred method, providing eight categories of RCC2 
expression based on staining proportion and intensity.19 
The same protocol was here used for analysis of the 
QUASAR2 trial cohort (details in online supplemental 
methods). Samples with a cytoplasmic Allred score <5 
were scored as having low expression of RCC2. Further, 
we developed a new protocol for scoring RCC2 expres-
sion, based on a monoclonal antibody against RCC2, fluo-
rescent staining and digital image analysis by applying the 
Vectra 3 Imaging platform and Inform analysis software 
(Akoya Biosciences) (online supplemental methods). 
This method was technically validated on the Norwegian 
series 1, and then used to analyse the Norwegian series 
2. With this new protocol, both cytoplasmic and nuclear 
expressions of RCC2 were scored. The fluorescence 
protocol provided continuous data for RCC2 expression, 
and the threshold for dichotomisation into high and 
low expression groups was set to match the percentage 
of tumours in each category in our previous analysis of 
Norwegian series 1 with the chromogenic protocol (41st 
percentile).19 This was also in line with the percentage of 
samples in each category in the QUASAR2 cohort (40.3% 
scored into the low RCC2 category with an Allred score 
<5). Totally 2916 CRCs from the three patient series were 
analysed for RCC2 expression, and 2696 (92.5%) tumours 
were evaluable. Online supplemental figure 1 shows an 
overview of patient samples included in the main anal-
yses, and online supplemental figure 2 shows an overview 
of the methodology applied to each cohort.
Statistical analyses
All statistical analyses were performed in RStudio 
V.1.1.383 with R V.3.6.1. All evaluable samples were used 
for association and correlation analyses (online supple-
mental figure 1). Correlations between RCC2 and clin-
icopathological and molecular variables were tested using 
the functions  fisher. test,  wilcox. test,  kruskal. test,  chisq. 
test and cor, depending on the nature of the variables 
(specified in the relevant tables). The continuous RCC2 
score was used for correlation analyses where applicable. 
The outcome evaluated was 5- year relapse- free survival 
(RFS) and was defined according to guidelines by Punt et 
al; time from surgery to death from any cause, or to recur-
rence.28 (Although disease- free survival (DFS) was used 
as endpoint in the original publication of the QUASAR2 
trial data,23 this definition of DFS corresponds to RFS in 
the guidelines by Punt et al,28 as information on second 
primary cancer events were not available). Only stage 
I–III patients with no residual tumour and a resection 
margin >1 mm (R0- resection) were included in survival 
analyses (online supplemental figure 1). Survival analyses 
were performed using the survival package (V.2.43–3). 







  median (IQR) −0.24 (1.06)* −0.31 (1.08)* § 5 (3)†
RCC2 score, dichotomised
  RCC2 Low 353 (41%) 309 (41%) § 439 (40%)
  RCC2 High 500 (59%) 444 (59%) 651 (60%)
  NA 69 45 106
Adjuvant chemotherapy (in R0- resected stage III patients)‡
  No 165 (74%) 109 (54%) <0.0001 0 (0%)
  Yes 58 (26%) 93 (46%) 1196 (100%)
P values were calculated to determine if there were any statistical differences between the two consecutive Norwegian series; Wilcoxon 
rank- sum test was used for age, Fisher’s exact test for sex, MSI, BRAF, KRAS, CDX2- status and chemotherapy and χ2 test for TNM stage, 
resection status and tumour location.
*Scaled continuous score.
†Allred score.
‡Adjuvant chemotherapy for stage III CRC was introduced in national guidelines in 1997, and therefore, a lower proportion of patients in 
Norwegian series 1 received such treatment. Additional details are provided in online supplemental table 2.
§Statistical analysis not relevant since the continuous RCC2 scores were scaled within each series and dichotomisation was performed such 
that the proportions of RCC2 low/high patients matched previous analysis, as described in the Methods section.
CRC, colorectal cancer; MSI, microsatellite instable; MSS, microsatellite stable; NA, Not available; RCC2, Regulator of chromosome 
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Kaplan- Meier survival curves were compared using the 
log- rank test. HRs and 95% CIs were estimated by univari-
able and multivariable Cox proportional hazards models. 
Covariables included in the multivariable model for 
patients with stage I–III CRC and who did not receive 
chemotherapy were based on clinical relevance, and also 
included relevant molecular variables, which are listed 
in table 1 (TP53 mutational status was not included in 
the model due to a low proportion of samples with avail-
able TP53 data). A full model including all variables 
was evaluated and only patients with complete data for 
all variables were included in the analysis. Since a large 
proportion of samples in the Norwegian series 2 were 
missing data for KRAS, BRAFV600E and CDX2, a multivar-
iable model excluding these covariables was also calcu-
lated. The two consecutive Norwegian series were pooled 
where relevant to increase the number of complete obser-
vations in statistical analyses. The multivariable analyses 
were stratified by cohort (Norwegian series 1 vs 2) since 
they were collected over different time periods and the 
Norwegian series 2 had a 5- year RFS of 64% compared 
with 58% in the Norwegian series 1 (online supplemental 
figure 3). The only statistically significant differences 
between these two series with respect to patient charac-
teristics was a somewhat higher proportion of stage I and 
a lower proportion of stage II in the Norwegian series 
2 compared with 1, and that a higher proportion of 
patients received adjuvant chemotherapy in the Norwe-
gian series 2 compared with 1 (table 1). This is explained 
by the fact that national guidelines were updated in 1997 
(described above). Therefore, analyses of the association 
between RCC2, adjuvant chemotherapy and survival were 
also performed within each series individually (online 
supplemental material). Survival analyses in the Norwe-
gian series were performed with RCC2 both as a dichoto-
mised and as a continuous variable, and results from anal-
yses of the continuous expression data are reported for all 
main models in online supplemental table 7. The Wald 
statistic was used to estimate the p value for continuous 
RCC2 scores and for the effects of individual variables 
in multivariable models. Testing of proportional hazards 
assumptions were performed with the  cox. zph function 
in the survival package. The assumption of proportional 
hazards was met in all analyses, except for in univariable 
survival analysis of age, TNM stage and CDX2 expression, 
as indicated in table 2, and the multivariable model in 
online supplemental table 6. This model was therefore 
also evaluated on stratification by TNM stage and age, 
which gave similar results for the prognostic value of 
RCC2 (data not included). The survMisc package was 
used to calculate the relative proportion of explained vari-
ation in 5- year RFS by each variable included in multivar-
iable analysis.29 Kaplan- Meier plots were generated using 
the survminer package (V.0.4.3). All statistical tests were 
two sided and p values <0.05 were considered significant. 
Bonferroni correction was used to account for multiple 
testing; subgroup analyses of RCC2 according to treat-
ment with chemotherapy (including stratified analysis by 
MSI- status) and according to TP53 status were adjusted 
by a factor of 8, and are reported in the relevant figures.
RESULTS
Robust method for fluorescent IHC-based analysis of RCC2 
expression
We implemented a new protocol for evaluation of in situ 
RCC2 protein expression on a continuous scale, based 
on fluorescent IHC staining. The protocol was found 
to be robust in Norwegian series 1 (figure 1A–D). First, 
specificity of the monoclonal antibody against RCC2 was 
confirmed in an HAP1 RCC2 knockout cell- line model 
(figure 1A). Second, RCC2 showed a varied nuclear and 
cytoplasmic staining pattern, with a large range of expres-
sion values (figure 1B). Third, fluorescence analyses of 
RCC2 expression using two different digital pathology 
solutions were concordant (Pearson’s r=0.90, figure 1C, 
described in online supplemental methods). Cyto-
plasmic and nuclear expression of RCC2 were correlated 
among tumours (Pearson’s r=0.77); however, cytoplasmic 
RCC2 staining was more strongly associated with patient 
outcome (online supplemental figure 4). This was in line 
with previous results,19 and all further analyses are there-
fore based on the cytoplasmic expression of RCC2. Impor-
tantly, the association between cytoplasmic RCC2 and 
5- year RFS among stage I–III patients was similar when 
compared with our previously published results from 
DAB- based visual scoring of RCC2 in this patient series 
(DAB- based visual: HR=1.51, p=0.0011; fluorescence- 
based digital: HR=1.56, p=0.0005; N=599, figure 1D).19 
We further compared methodologies by association anal-
yses with molecular variables (online supplemental table 
3). There were no significant associations between RCC2 
expression and KRAS mutations, BRAFV600E mutations or 
CDX2 expression by either method. Low RCC2 expression 
was more frequently found in microsatellite stable (MSS) 
tumours, although this association was not significant by 
the new RCC2 scoring method with monoclonal antibody 
and digital analysis (p=0.06).
Low RCC2 expression is associated with advanced cancer 
stage
Totally 2696 CRCs were scored for RCC2 expression 
across the two Norwegian series and QUASAR2 (92.5% 
of the analysed samples, online supplemental figure 1). 
Of these, 1101 (41%) were scored with low RCC2 expres-
sion (details in methods). Low RCC2 expression was 
associated with higher cancer stage in all three cohorts 
(p<0.001, online supplemental tables 4 and 5), but not 
with any other clinicopathological factors (patient age, 
sex or tumour location) or molecular markers (KRAS, 
BRAFV600E, TP53 mutation status or CDX2 expression). A 
significant association with MSI status was found only in 
Norwegian series 2 (p=0.0042). Of note, RCC2 expression 
was not different between patients who did and did not 
receive adjuvant chemotherapy for stage III CRC in the 
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between the two adjuvant treatment groups in QUASAR2 
(online supplemental table 5).
Low expression of RCC2 is associated with benefit from 
chemotherapy in stage III CRC
Analysis of stage I–III patients in the independent 
Norwegian series 2 validated the prognostic value of low 
RCC2 expression for 5- year RFS (HR 1.50, 95% CI 1.16 
to 1.95, log- rank p=0.002, N=607, figure 2A). However, 
there was no significant difference in the 5- year RFS 
rate according to RCC2 expression in the QUASAR2 
cohort (HR 1.13, 95% CI 0.90 to 1.42, log- rank p=0.28, 
N=1090, figure 2B), irrespective of cancer stage (stage 
II or III, online supplemental figure 5) or treatment 
regimen (online supplemental figure 6). As all patients 
in QUASAR2 received adjuvant chemotherapy, and this 
was the case for only 9% and 16% of stage I–III CRCs 
in the Norwegian series 1 and 2, respectively (online 
supplemental table 2), we speculated that this discrep-
ancy could be due to an interaction between RCC2 and 
chemotherapy. The two Norwegian series were pooled 
for further analyses, and this confirmed that RCC2 was 
not prognostic in the subgroup of patients who did 
receive adjuvant chemotherapy (HR 0.90, 95% CI 0.55 
to 1.48, log- rank p=0.67, N=158, figure 2C), irrespective 
of the treatment type (online supplemental figure 7). In 
contrast, low expression of RCC2 was significantly asso-
ciated with worse outcome among patients who did not 
receive chemotherapy (HR 1.54, 95% CI 1.28 to 1.86, 
log- rank p<0.0001, N=1117, figure 2C and online supple-
mental figure 8). A test for interaction in stage III patients 
showed that adjuvant chemotherapy was associated with 
higher 5- year RFS rate in patients with low RCC2 expres-
sion (pinteraction=0.047, figure 3A,B and online supple-
mental figure 9). Stratification according to MSI status 
further showed that low expression of RCC2 was associ-
ated with benefit from chemotherapy only in the MSS 
subgroup (pinteraction=0.028, figure 3C and online supple-
mental figure 10). Analyses excluding rectal cancer 
patients showed the same trend as when all patients 
were analysed together (online supplemental figures 11 
Table 2 Univariable and multivariable 5- year relapse- free survival analyses in stage I–III chemotherapy untreated patients in 
the pooled Norwegian series




HR (95 % CI) P value HR (95 % CI) P value
RCC2 High 691 1 – 1 –
Low 426 1.54 (1.28 to 1.86) <0.0001 1.45 (1.09 to 1.94) 0.012
Sex Female 620 1 – 1 –
Male 577 1.09 (0.91 to 1.30) 0.37 1.12 (0.84 to 1.50) 0.43
Age Below median† 520 1 – 1 –
Above or equal to 
median†
677 1.83 (1.51 to 2.22) <0.0001* 1.85 (1.35 to 2.54) 0.0001
TNM stage I 302 1 – 1 –
II 622 1.71 (1.32 to 2.21) <0.0001* 1.34 (0.90 to 2.02) 0.15
III 273 3.12 (2.37 to 4.10) <0.0001* 2.56 (1.70 to 3.86) <0.0001
Tumour location Right colon 469 1 – 1 –
Left colon 332 1.19 (0.96 to 1.49) 0.12 1.33 (0.92 to 1.92) 0.13
Rectum 367 0.99 (0.79 to 1.24) 0.95 1.16 (0.77 to 1.73) 0.48
Synchronous 29 1.19 (0.66 to 2.14) 0.56 0.83 (0.30 to 2.30) 0.71
MSI status MSI 198 1 – 1 –
MSS 911 1.28 (0.99 to 1.67) 0.059 2.47 (1.32 to 4.63) 0.0047
BRAFV600E 
mutational status
Wild- type 652 1 – 1 –
Mutated 124 0.95 (0.69 to 1.30) 0.75 1.72 (1.00 to 2.96) 0.051
KRAS mutational 
status
Wild- type 490 1 – 1 –
Mutated 209 1.22 (0.95 to 1.56) 0.13 1.07 (0.77 to 1.47) 0.70
CDX2 expression 
status
Positive 610 1 – 1 –
Negative 68 1.22 (0.83 to 1.79) 0.31* 1.86 (1.15 to 3.02) 0.012
Multivariable analysis was stratified by series.
*Violates proportional hazards assumption in univariable analysis.
†Above/below median age (73) of all patients in the pooled series.
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and 12). Exploratory analyses suggested that the benefit 
from chemotherapy in the RCC2- low subgroup was inde-
pendent of CDX2 expression, but the number of tumours 
with low CDX2 expression was too small to draw a firm 
conclusion (online supplemental figure 13).
Prognostic value of RCC2 is independent of clinicopathological 
and molecular markers in patients with no adjuvant treatment
The prognostic value of RCC2 among patients in the 
pooled Norwegian series who did not receive adjuvant 
chemotherapy was further analysed in a full multivariable 
Figure 1 Methodological development and technical validation of in situ protein expression analysis of RCC2 in the 
Norwegian series 1. (A) HAP1 wild- type cells showing staining (top) and HAP1 RCC2 knockout cells showing absence of 
staining (bottom) against RCC2. Scale bar equals 10 µm (×40). (B) Top: one of the TMAs in the Norwegian series 1; RCC2 is 
shown in yellow, epithelial/tumour tissue in red and DAPI in blue. Scale bar equals 2 mm. Bottom left: a sample demonstrating 
absence of immunoreactivity against RCC2. Middle: a sample with predominant nuclear localisation of RCC2, having 
also some in the cytoplasm. Right: a sample showing strong staining against RCC2 in both nuclear and cytoplasmic cell 
compartments. Where on the scale of the continuous cytoplasmic RCC2 scores these samples are located is shown on the 
density plot below. Scale bar equals 100 µm in tumour core images (lower right portion of each image is ×3 zoomed). (C) 
Comparison of cytoplasmic RCC2- scoring at two different institutions using different digital image analysis platforms (x- axis; 
scores obtained at FIMM, y- axis; scores obtained at OUH, details in online supplemental methods). Correlation coefficient was 
calculated by Pearson’s method. (D) The association between RCC2 and 5- year relapse- free survival in stage I–III patients was 
assessed using the original method for scoring RCC2 (polyclonal antibody, chromogenic staining and Allred scoring through 
visual analysis, data previously published in ref. 19; left panel), and using the new method for scoring RCC2 (monoclonal 
antibody, fluorescent staining and digital image analysis; right panel). Only samples scored by both methods were included 
in the comparison. DAPI, 4',6- diamidino-2- phenylindole; DIA, digital image analysis; FIMM, Institute for Molecular Medicine 
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Figure 2 Five- year survival according to RCC2 status in stage I–III patients of the Norwegian series 2 (A), the QUASAR2 
cohort (B), and in the pooled Norwegian series split by adjuvant chemotherapy (C). The relative proportion of explained 
variation in 5- year relapse- free survival for each clinicopathological and molecular variable in multivariable analysis of stage 
I–III CRC patients who did not receive adjuvant chemotherapy was calculated (D). CRC, colorectal cancer; MSI, microsatellite 
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Cox model including other molecular and clinicopatho-
logical parameters. RCC2 retained independent prog-
nostic value in this model (HR 1.45, 95% CI 1.09 to 1.94, 
p=0.012, N=521, table 2). A model excluding KRAS, 
BRAFV600E and CDX2 as covariables allowed for inclusion of 
more patients and gave similar results for the prognostic 
value of RCC2 (online supplemental table 6). RCC2 was 
estimated to contribute 9.6% of the relative proportion of 
explained variation in 5- year RFS (figure 2D). Although 
clinicopathological factors contributed with the majority 
(71.3%) of explained variation (figure 2D), RCC2 had a 
stronger prognostic impact than any of the other molec-
ular variables (≤8.1% of explained variation). The rela-
tively low number of patients with known TP53 mutation 
status (a subset of the Norwegian series 2 only, N=347, 
table 1) precluded inclusion in multivariable analysis. 
Figure 3 Low RCC2 is associated with benefit from chemotherapy in stage III patients of the pooled Norwegian series. 
Benefit of adjuvant chemotherapy was assessed in all stage III patients (A), according to low/high RCC2 (B) and according to 
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However, RCC2 was found to be significantly associated 
with patient outcome only in TP53 mutated (HR 2.58, 
95% CI 1.34 to 4.95, p=0.0031, adj. p=0.025), not in TP53 
wild- type tumours (HR 1.06, 95% CI 0.47 to 2.39, p=0.89, 
adj. p=1) (pinteraction=0.089, online supplemental figure 
14).
DISCUSSION
Optimisation of adjuvant chemotherapy in stage II and III 
CRC is an ongoing debate,30 in particular for the subgroup 
of patients with MSS cancers. The decision to treat in 
this setting is currently based on tumour stage, colon or 
rectal cancer, prognostic factors and patient tolerability 
to treatment. Our results suggest that patients with stage 
III MSS CRC and low expression of the RCC2 protein 
may have superior benefit from adjuvant chemotherapy 
than patients with high RCC2 expression. We have previ-
ously reported that RCC2 is an independent prognostic 
biomarker in primary CRC (in Norwegian series 1).19 In 
the present study, this was validated in an independent 
series from the same hospital, but only in patients who 
did not receive adjuvant chemotherapy. There was a statis-
tically significant interaction between RCC2 and chemo-
therapy for outcome in the combined Norwegian series, 
implying that a low expression of RCC2 was predictive of 
the effect of chemotherapy in this retrospective analysis 
of an observational study cohort treated according to 
national guidelines. In support of this predictive effect, 
preclinical studies of cell line models from ovarian, lung, 
cervical and breast cancer have demonstrated an associa-
tion between high expression of RCC2 and resistance to 
chemotherapy.17 21
We could only analyse interactions between RCC2 and 
chemotherapy in patients with stage III CRC, due to the low 
number of stage I and II patients who received such treat-
ment. However, the association between low RCC2 expres-
sion and poor prognosis in chemotherapy- untreated 
cancers was strong also in stage II (online supplemental 
figure 15), suggesting a potential to improve the outcome 
of patients in the low- RCC2 subgroup also in this stage. In 
fact, RCC2 was found to be an independent prognostic 
biomarker in multivariable analysis of chemotherapy- 
untreated stage I–III patients, after adjusting for TNM 
stage, patient age, sex, tumour location, MSI status, 
CDX2 expression, BRAFV600E- and KRAS mutation status. 
A limitation in this analysis was the missing information 
on the molecular variables CDX2, BRAFV600E and KRAS for 
a proportion of the patients. However, results for RCC2 
analysed in a multivariable model excluding these vari-
ables, which allowed for inclusion of substantially more 
patients, were virtually identical. Furthermore, the associ-
ation between RCC2 and benefit from chemotherapy was 
independent of treatment regimen, and the results were 
similar for 5- fluorouracil monotherapy or in combina-
tion with oxaliplatin. Loss of CDX2 expression has been 
proposed as a biomarker for benefit from chemotherapy 
in CRC, also in our patient cohorts.11 12 RCC2 seemed to 
be independent of CDX2 in this setting, but due to the 
low number of CDX2 negative cases, we cannot firmly 
conclude on the prognostic relationship between RCC2, 
CDX2 and adjuvant chemotherapy.
A study by Song et al has reported that wild- type TP53 
may transcriptionally activate RCC2, which in turn 
inhibits RAC1 and thus prevents formation of metas-
tases.20 Although these results are interesting, we did not 
find any differences in RCC2 expression levels related 
to TP53 mutational status. However, we did find low 
RCC2 expression to be associated with a poor patient 
prognosis only in TP53 mutated, and not in TP53 wild- 
type tumours. It is important to note that in our study 
we analysed cytoplasmic RCC2 expression, since this was 
found to be a stronger predictor of patient outcome 
than nuclear expression.19 It is possible that this relates 
to the interaction RCC2 has with RAC1 in the cytoplasm, 
in contrast to its role in the nucleus where RCC2 regu-
lates the chromosomal passenger complex. However, 
the nuclear and cytoplasmic expressions of RCC2 were 
strongly correlated, and additional studies are needed to 
clarify the functional relationship between RCC2 and its 
biomarker value. Notably, high expression of RCC2 has 
been linked to epithelial- mesenchymal transition and 
worse outcome in other cancer types, including lung and 
breast cancer, suggesting that the effect of RCC2 might be 
cancer type- dependent.16 31
In the current study, we developed and employed a 
new methodological approach for in situ analysis of 
RCC2 by IHC, including the use of a validated mono-
clonal antibody, which facilitates potential future use 
in the clinic. We used fluorescent staining and digital 
image analysis, which together offer continuous scoring 
of biomarkers, and increases throughput of TMA- 
analyses by eliminating the process of visual scoring. 
Considering the different scale of these continuous 
data compared with the categorised RCC2 expression 
data provided by DAB- staining and visual analysis by 
the Allred method, we did not perform benchmarking 
of the two methods. However, due to the large dynamic 
linear range and continuous scoring scale provided by 
the new method, this approach is well suited for accu-
rate and objective biomarker analyses.32 33
In summary, we have shown that low expression 
of RCC2 is a biomarker for a poor prognosis in non- 
metastatic CRC, and our data suggest that it may also be 
a predictive marker for a survival benefit from adjuvant 
chemotherapy.
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